SARTORIUS STEDIM, DEAR TO THE CORE (SELL; -29% DOWNSIDE)
23/02/21 -" Sartorius Stedim Biotech (Sell, France) ranks as a top-notch asset, with industry-leading return metrics (FY20 ROE of 26% vs 14% for AV peers). Since we noted its phenomenal run almost two years ..."
Pages
61
Language
English
Published on
23/02/21
You may also be interested by these reports :
11/07/25
Given the numerous new product launches, high adoption of existing products, increased presence in point-of-care testing and robust balance sheet, we ...
07/07/25
Sartorius (BUY; Germany), a historically pristine business, has fallen off its perch. Following the big and expensive bet on Polyplus, Sartorius ...
04/07/25
We’ve updated our forecasts to reflect the latest asset disposals, including Baywater (expected to generate €60m revenue in FY24/25 ending June ...
04/07/25
Among Europe’s holding companies, Exor (BUY; Netherlands) is one of the rare, truly active stewards of capital: unafraid to rotate its portfolio, ...